These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 19953653

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Increased dopamine D2 receptor binding and enhanced apomorphine-induced locomotor activity in mu-opioid receptor knockout mice.
    Tien LT, Park Y, Fan LW, Ma T, Loh HH, Ho IK.
    Brain Res Bull; 2003 Jun 30; 61(1):109-15. PubMed ID: 12788214
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Dual alteration of limbic dopamine D1 receptor-mediated signalling and the Akt/GSK3 pathway in dopamine D3 receptor mutants during the development of methamphetamine sensitization.
    Chen PC, Lao CL, Chen JC.
    J Neurochem; 2007 Jan 30; 100(1):225-41. PubMed ID: 17101033
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Involvement of adenosine A2A and dopamine receptors in the locomotor and sensitizing effects of cocaine.
    Filip M, Frankowska M, Zaniewska M, Przegaliński E, Muller CE, Agnati L, Franco R, Roberts DC, Fuxe K.
    Brain Res; 2006 Mar 10; 1077(1):67-80. PubMed ID: 16516871
    [Abstract] [Full Text] [Related]

  • 29. Nullifying drug-induced sensitization: behavioral and electrophysiological evaluations of dopaminergic and serotonergic ligands in methamphetamine-sensitized rats.
    McDaid J, Tedford CE, Mackie AR, Dallimore JE, Mickiewicz AL, Shen F, Angle JM, Napier TC.
    Drug Alcohol Depend; 2007 Jan 05; 86(1):55-66. PubMed ID: 16762517
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Sensorimotor gating effects produced by repeated dopamine agonists in a paradigm favoring environmental conditioning.
    Feifel D, Priebe K, Johnstone-Miller E, Morgan CJ.
    Psychopharmacology (Berl); 2002 Jul 05; 162(2):138-46. PubMed ID: 12110991
    [Abstract] [Full Text] [Related]

  • 32. Effects of D2 or combined D1/D2 receptor antagonism on the methamphetamine-induced one-trial and multi-trial behavioral sensitization of preweanling rats.
    Mohd-Yusof A, Veliz A, Rudberg KN, Stone MJ, Gonzalez AE, McDougall SA.
    Psychopharmacology (Berl); 2016 Mar 05; 233(5):893-903. PubMed ID: 26650612
    [Abstract] [Full Text] [Related]

  • 33. Neuropsychotoxicity of abused drugs: effects of serotonin receptor ligands on methamphetamine- and cocaine-induced behavioral sensitization in mice.
    Ago Y, Nakamura S, Baba A, Matsuda T.
    J Pharmacol Sci; 2008 Jan 05; 106(1):15-21. PubMed ID: 18198473
    [Abstract] [Full Text] [Related]

  • 34. Altered dopamine D1 and D2 receptor mRNA expression in mesencephalon from mice exposed to repeated treatments with methamphetamine and cannabinoid CB1 agonist methanandamide.
    Landa L, Jurajda M, Sulcova A.
    Neuro Endocrinol Lett; 2012 Jan 05; 33(4):446-52. PubMed ID: 22936253
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Ciproxifan, a histamine H₃-receptor antagonist / inverse agonist, modulates methamphetamine-induced sensitization in mice.
    Motawaj M, Arrang JM.
    Eur J Neurosci; 2011 Apr 05; 33(7):1197-204. PubMed ID: 21366724
    [Abstract] [Full Text] [Related]

  • 37. The role of tissue plasminogen activator in methamphetamine-related reward and sensitization.
    Nagai T, Noda Y, Ishikawa K, Miyamoto Y, Yoshimura M, Ito M, Takayanagi M, Takuma K, Yamada K, Nabeshima T.
    J Neurochem; 2005 Feb 05; 92(3):660-7. PubMed ID: 15659235
    [Abstract] [Full Text] [Related]

  • 38. Attenuated methamphetamine-induced locomotor sensitization in serotonin transporter knockout mice is restored by serotonin 1B receptor antagonist treatment.
    Igari M, Shen HW, Hagino Y, Fukushima S, Kasahara Y, Lesch KP, Murphy DL, Hall FS, Uhl GR, Ikeda K, Yaegashi N, Sora I.
    Behav Pharmacol; 2015 Feb 05; 26(1-2):167-79. PubMed ID: 25485646
    [Abstract] [Full Text] [Related]

  • 39. Central PGE2 exhibits anxiolytic-like activity via EP1 and EP4 receptors in a manner dependent on serotonin 5-HT1A, dopamine D1 and GABAA receptors.
    Suzuki C, Miyamoto C, Furuyashiki T, Narumiya S, Ohinata K.
    FEBS Lett; 2011 Jul 21; 585(14):2357-62. PubMed ID: 21693121
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.